Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Nepafenac (Nevanac®) is recommended for use within NHS Wales for reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients. |
|||
|
|||
Medicine details |
|||
| Medicine name | nepafenac (Nevanac®) | ||
| Formulation | 1 mg/ml eye drops | ||
| Reference number | 1509 | ||
| Indication | Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients |
||
| Company | Alcon Laboratories (UK) Ltd | ||
| BNF chapter | Eye | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 1813 | ||
| NMG meeting date | 19/06/2013 | ||
| AWMSG meeting date | 17/07/2013 | ||
| Ratification by Welsh Government | 14/08/2013 | ||
| Date of issue | 16/08/2013 | ||
| Date of last review | 30/09/2016 | ||